Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3861-3870 Newer>

The Motley Fool July 16, 2007 Brian Lawler	Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.
The Motley Fool July 16, 2007 Brian Orelli	Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price.
Chemistry World July 13, 2007 Hepeng Jia	Chinese Legislation to Increase Drug Safety A long-awaited amendment to China's drug registration system is expected to discipline the country's medical sector and boost the pharmaceutical industry.
BusinessWeek July 23, 2007 Gene G. Marcial	At Ziopharm, Arsenic Is Not So Toxic Ziopharm uses arsenic that is organic. It's stock is rated a buy.
The Motley Fool July 12, 2007 Brian Lawler	Dendreon Under Attack Following an unfavorable regulatory decision for its lead drug Provenge, the biotech is now the focus of an SEC inquiry.
The Motley Fool July 12, 2007 Brian Orelli	Supporting the Little Company Tercica gets a partnership with Genentech. As part of the deal, Genentech will purchase $4 million in Tercica stock for about $5.65 per share. Some investors think that Genentech is underpaying.
The Motley Fool July 11, 2007 Brian Lawler	Why Depomed Shares Were Dumped In a recent trial, a pain medication wasn't as effective as had been hoped. Investors, take note.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
The Motley Fool July 11, 2007 Brian Orelli	Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note.
The Motley Fool July 10, 2007 Brian Orelli	Sometimes, the Same Is Good Enough Bristol-Myers Squibb's new drug doesn't work better, but it's easier to take. Investors, take note.
<Older 3861-3870 Newer> Return to current articles.